Dean John Naisbitt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9147990/publications.pdf

Version: 2024-02-01

171 papers	9,160 citations	38660 50 h-index	46693 89 g-index
175 all docs	175 docs citations	175 times ranked	7623 citing authors

#	Article	IF	Citations
1	HLA Alleleâ€"Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction. Annual Review of Pharmacology and Toxicology, 2022, 62, .	4.2	8
2	Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity. Toxicological Sciences, 2022, 186, 58-69.	1.4	13
3	Characterization of Teicoplanin-Specific T-Cells from Drug NaÃ¯ve Donors Expressing HLA-A*32:01. Chemical Research in Toxicology, 2022, 35, 199-202.	1.7	1
4	Does immune checkpoint inhibitor therapy increase the frequency of adverse reactions to concomitant medications?. Clinical and Experimental Allergy, 2022, 52, 600-603.	1.4	2
5	Tâ€cellâ€mediated hypersensitivity to lumacaftor and ivacaftor in cystic fibrosis. Pediatric Allergy and Immunology, 2022, 33, .	1.1	1
6	Advances in Our Understanding of the Interaction of Drugs with T-cells: Implications for the Discovery of Biomarkers in Severe Cutaneous Drug Reactions. Chemical Research in Toxicology, 2022, 35, 1162-1183.	1.7	2
7	Biopsy Pathology and Immunohistochemistry of a Case of Immuneâ€Mediated Drugâ€Induced Liver Injury With Atabecestat. Hepatology, 2021, 73, 452-455.	3.6	10
8	Drug allergy to CFTR modulator therapy associated with lumacaftor-specific CD4+ T lymphocytes. Journal of Allergy and Clinical Immunology, 2021, 147, 753-756.	1.5	7
9	Drugâ€specific Tâ€cell responses in patients with liver injury following treatment with the BACE inhibitor atabecestat. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1825-1835.	2.7	12
10	Prospective observational study of SARS-CoV-2 infection, transmission and immunity in a cohort of households in Liverpool City Region, UK (COVID-LIV): a study protocol. BMJ Open, 2021, 11, e048317.	0.8	1
11	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 2021, 12, 2055.	5.8	102
12	In-Vitro Approaches to Predict and Study T-Cell Mediated Hypersensitivity to Drugs. Frontiers in Immunology, 2021, 12, 630530.	2.2	13
13	Characterization of T-Cell Responses to SMX and SMX-NO in Co-Trimoxazole Hypersensitivity Patients Expressing HLA-B*13:01. Frontiers in Immunology, 2021, 12, 658593.	2.2	14
14	HLA-B*13 :01 Is a Predictive Marker of Dapsone-Induced Severe Cutaneous Adverse Reactions in Thai Patients. Frontiers in Immunology, 2021, 12, 661135.	2.2	29
15	T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab. , 2021, 9, e002521.		10
16	Extracellular Vesicles from Human Plasma Show a Distinctive Proteome and miRNome Profile in Patients with Severe Cutaneous Adverse Reactions. Chemical Research in Toxicology, 2021, 34, 1738-1748.	1.7	3
17	Deciphering Adverse Drug Reactions:In VitroPriming and Characterization of Vancomycin-Specific T Cells From Healthy Donors Expressing HLA-A*32:01. Toxicological Sciences, 2021, 183, 139-153.	1.4	9
18	Drug haptenâ€specific Tâ€cell activation: Current status and unanswered questions. Proteomics, 2021, 21, e2000267.	1.3	9

#	Article	IF	Citations
19	HLA Class-IIâ€'Restricted CD8+ T Cells Contribute to the Promiscuous Immune Response in Dapsone-Hypersensitive Patients. Journal of Investigative Dermatology, 2021, 141, 2412-2425.e2.	0.3	12
20	Shedding Light on Drug-Induced Liver Injury: Activation of T Cells From Drug Naive Human Donors With Tolvaptan and a Hydroxybutyric Acid Metabolite. Toxicological Sciences, 2021, 179, 95-107.	1.4	2
21	T-Cell Activation by Low Molecular Weight Drugs and Factors That Influence Susceptibility to Drug Hypersensitivity. Chemical Research in Toxicology, 2020, 33, 77-94.	1.7	9
22	Modification of the cyclopropyl moiety of abacavir provides insight into the structure activity relationship between HLAâ€B*57:01 binding and Tâ€cell activation. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 636-647.	2.7	19
23	Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models. Nature Reviews Drug Discovery, 2020, 19, 131-148.	21.5	153
24	Immune dysregulation increases the incidence of delayedâ€type drug hypersensitivity reactions. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 781-797.	2.7	21
25	Characterization of Clozapine-Responsive Human T Cells. Journal of Immunology, 2020, 205, 2375-2390.	0.4	9
26	Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury. Chemical Research in Toxicology, 2020, 33, 2745-2748.	1.7	13
27	Cell Membrane Transporters Facilitate the Accumulation of Hepatocellular Flucloxacillin Protein Adducts: Implication in Flucloxacillin-Induced Liver Injury. Chemical Research in Toxicology, 2020, 33, 2939-2943.	1.7	7
28	Identification of Flucloxacillin-Haptenated HLA-B*57:01 Ligands: Evidence of Antigen Processing and Presentation. Toxicological Sciences, 2020, 177, 454-465.	1.4	21
29	HLA DRB1*15:01-DQB1*06:02-Restricted Human CD4+ T Cells Are Selectively Activated With Amoxicillin-Peptide Adducts. Toxicological Sciences, 2020, 178, 115-126.	1.4	14
30	Development of an Improved T-cell Assay to Assess the Intrinsic Immunogenicity of Haptenic Compounds. Toxicological Sciences, 2020, 175, 266-278.	1.4	13
31	Current perspective of the etiopathogenesis of delayed-type, and T-cellâ€"mediated drug-related skin diseases. Journal of Allergy and Clinical Immunology, 2020, 145, 1142-1144.	1.5	8
32	Characterization of amoxicillin and clavulanic acid specific Tâ€cell clones from patients with immediate drug hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2562-2573.	2.7	10
33	Definition of Haptens Derived from Sulfamethoxazole: In Vitro and in Vivo. Chemical Research in Toxicology, 2019, 32, 2095-2106.	1.7	14
34	Exosomal Transport of Hepatocyteâ€Derived Drugâ€Modified Proteins to the Immune System. Hepatology, 2019, 70, 1732-1749.	3.6	33
35	Dapsoneâ€•and nitroso dapsoneâ€specific activation of T cells from hypersensitive patients expressing the risk allele HLAâ€B*13:01. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1533-1548.	2.7	37
36	Characterization of Healthy Donor-Derived T-Cell Responses Specific to Telaprevir Diastereomers. Toxicological Sciences, 2019, 168, 597-609.	1.4	3

#	Article	IF	Citations
37	The skin as a metabolic and immune-competent organ: Implications for drug-induced skin rash. Journal of Immunotoxicology, 2019, 16, 1-12.	0.9	20
38	Up-Regulation of T-Cell Activation MicroRNAs in Drug-Specific CD4⁺ T-Cells from Hypersensitive Patients. Chemical Research in Toxicology, 2018, 31, 454-461.	1.7	13
39	Application of in Vitro T Cell Assay Using Human Leukocyte Antigen-Typed Healthy Donors for the Assessment of Drug Immunogenicity. Chemical Research in Toxicology, 2018, 31, 165-167.	1.7	16
40	Immune drug-induced liver disease and drugs. Current Opinion in Toxicology, 2018, 10, 46-53.	2.6	8
41	Immune Mechanisms in Drug-Induced Liver Injury. Methods in Pharmacology and Toxicology, 2018, , 511-531.	0.1	2
42	Î²-Lactam hypersensitivity involves expansion of circulating and skin-resident TH22Âcells. Journal of Allergy and Clinical Immunology, 2018, 141, 235-249.e8.	1.5	34
43	HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors. Chemical Research in Toxicology, 2018, 31, 1022-1024.	1.7	9
44	Mechanisms leading to T-cell activation in drug hypersensitivity. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 317-324.	1.1	25
45	State-of-the-art and new options to assess T cell activation by skin sensitizers: Cosmetics Europe Workshop. ALTEX: Alternatives To Animal Experimentation, 2018, 35, 179-192.	0.9	21
46	Identification of drug- and drug-metabolite immune responses originating from both naive and memory T cells. Journal of Allergy and Clinical Immunology, 2017, 140, 578-581.e5.	1.5	10
47	Definition of the Nature and Hapten Threshold of the Î²-Lactam Antigen Required for T Cell Activation In Vitro and in Patients. Journal of Immunology, 2017, 198, 4217-4227.	0.4	54
48	Characterization of Drug-Specific Signaling Between Primary Human Hepatocytes and Immune Cells. Toxicological Sciences, 2017, 158, 76-89.	1.4	37
49	Human leukocyte antigen and idiosyncratic adverse drug reactions. Drug Metabolism and Pharmacokinetics, 2017, 32, 21-30.	1.1	32
50	Trimethoprim-induced aseptic meningism. British Journal of Hospital Medicine (London, England: 2005), 2017, 78, 108-109.	0.2	3
51	Dapsone and Nitroso Dapsone Activation of NaÄ±Ì^ve T-Cells from Healthy Donors. Chemical Research in Toxicology, 2017, 30, 2174-2186.	1.7	18
52	Assessment of Antipiperacillin IgG Binding to Structurally Related Drug Protein Adducts. Chemical Research in Toxicology, 2017, 30, 2097-2099.	1.7	6
53	The Effect of Inhibitory Signals on the Priming of Drug Haptenâ€"Specific T Cells That Express Distinct VÎ² Receptors. Journal of Immunology, 2017, 199, 1223-1237.	0.4	41
54	From the Cover: Characterization of Isoniazid-Specific T-Cell Clones in Patients with anti-Tuberculosis Drug-Related Liver and Skin Injury. Toxicological Sciences, 2017, 155, 420-431.	1.4	31

#	Article	IF	Citations
55	Detection of drugâ€responsive B lymphocytes and antidrug IgG in patients with Î²â€lactam hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 896-907.	2.7	14
56	New Approaches to Investigate Drug-Induced Hypersensitivity. Chemical Research in Toxicology, 2017, 30, 239-259.	1.7	18
57	Drugâ€specific CD4⁺Tâ€cell immune responses are responsible for antituberculosis drugâ€induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome. British Journal of Dermatology, 2017, 176, 378-386.	1.4	42
58	Immunological Mechanisms of Drug Hypersensitivity. Current Pharmaceutical Design, 2017, 22, 6734-6747.	0.9	8
59	Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury. Allergy, Asthma and Immunology Research, 2016, 8, 3.	1.1	52
60	Detection of Primary T Cell Responses to Drugs and Chemicals in HLA-Typed Volunteers: Implications for the Prediction of Drug Immunogenicity. Toxicological Sciences, 2016, 154, 416-429.	1.4	40
61	Effect of Repeated Daily Dosing with 2,4-Dinitrochlorobenzene on Glutathione Biosynthesis and Nrf2 Activation in Reconstructed Human Epidermis. Toxicological Sciences, 2016, 154, 5-15.	1.4	7
62	Amoxicillin and Clavulanate Form Chemically and Immunologically Distinct Multiple Haptenic Structures in Patients. Chemical Research in Toxicology, 2016, 29, 1762-1772.	1.7	48
63	Detection of Drug-Responsive T-Lymphocytes in a Case of Fatal Antituberculosis Drug-Related Liver Injury. Chemical Research in Toxicology, 2016, 29, 1793-1795.	1.7	11
64	No Evidence for Drug-Specific Activation of Circulating T Cells from Patients with HLA-DRB1*07:01-Restricted Lapatinib-Induced Liver Injury. Chemical Research in Toxicology, 2016, 29, 2111-2113.	1.7	8
65	Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury. Allergy, Asthma and Immunology Research, 2016, 8, 3.	1.1	2
66	The chemical, genetic and immunological basis of idiosyncratic drugâ€"induced liver injury. Human and Experimental Toxicology, 2015, 34, 1310-1317.	1.1	28
67	HLAâ€DQ alleleâ€restricted activation of nitroso sulfamethoxazoleâ€specific CD4â€positive T lymphocytes from patients with cystic fibrosis. Clinical and Experimental Allergy, 2015, 45, 1305-1316.	1.4	12
68	Characterization of amoxicillinâ€and clavulanic acidâ€specific T cells in patients with amoxicillinâ€clavulanateâ€"induced liver injury. Hepatology, 2015, 62, 887-899.	3.6	83
69	Towards depersonalized abacavir therapy. Aids, 2015, 29, 2385-2395.	1.0	15
70	Auto-oxidation of Isoniazid Leads to Isonicotinic-Lysine Adducts on Human Serum Albumin. Chemical Research in Toxicology, 2015, 28, 51-58.	1.7	33
71	Characterization of Peroxidases Expressed in Human Antigen Presenting Cells and Analysis of the Covalent Binding of Nitroso Sulfamethoxazole to Myeloperoxidase. Chemical Research in Toxicology, 2015, 28, 144-154.	1.7	22
72	Promiscuous T-cell responses to drugs and drug-haptens. Journal of Allergy and Clinical Immunology, 2015, 136, 474-476.e8.	1.5	41

#	Article	IF	Citations
73	Glutathione metabolism in the HaCaT cell line as a model for the detoxification of the model sensitisers 2,4-dinitrohalobenzenes in human skin. Toxicology Letters, 2015, 237, 11-20.	0.4	19
74	Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy. Journal of Allergy and Clinical Immunology, 2015, 136, 262-271.e2.	1.5	51
75	Are drug metabolites able to cause T-cell-mediated hypersensitivity reactions?. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 357-368.	1.5	15
76	In Vitro Priming of NaÄ±Ì‚ve T-cells with p-Phenylenediamine and Bandrowskiâ€™s Base. Chemical Research in Toxicology, 2015, 28, 2069-2077.	1.7	16
77	Mechanism-Based Markers of Drug-Induced Liver Injury to Improve the Physiological Relevance and Predictivity of In Vitro Models. Applied in Vitro Toxicology, 2015, 1, 175-186.	0.6	5
78	Activation of Flucloxacillin-Specific CD8+ T-Cells With the Potential to Promote Hepatocyte Cytotoxicity in a Mouse Model. Toxicological Sciences, 2015, 146, 146-156.	1.4	27
79	The importance of haptenâ€"protein complex formation in the development of drug allergy. Current Opinion in Allergy and Clinical Immunology, 2014, 14, 293-300.	1.1	49
80	Negative Regulation by PD-L1 during Drug-Specific Priming of IL-22â€"Secreting T Cells and the Influence of PD-1 on Effector T Cell Function. Journal of Immunology, 2014, 192, 2611-2621.	0.4	50
81	HLA Restriction of Carbamazepine-Specific T-Cell Clones from an HLA-A*31:01-Positive Hypersensitive Patient. Chemical Research in Toxicology, 2014, 27, 175-177.	1.7	36
82	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2014, 15, 829-840.	5.1	296
83	Negative regulation by Programmed Death Ligandâ€1 during drugâ€specific priming of Tâ€cells and the influence of Programmed Deathâ€1 on effector Tâ€cell function. Clinical and Translational Allergy, 2014, 4, O2.	1.4	0
84	InÂVitro Diagnosis of Delayed-type Drug Hypersensitivity. Immunology and Allergy Clinics of North America, 2014, 34, 691-705.	0.7	18
85	Abacavir Forms Novel Cross-Linking Abacavir Protein Adducts in Patients. Chemical Research in Toxicology, 2014, 27, 524-535.	1.7	21
86	Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Archives of Toxicology, 2013, 87, 1315-1530.	1.9	1,089
87	Activation of carbamazepine-responsive T-cell clones with metabolically inert halogenated derivatives. Journal of Allergy and Clinical Immunology, 2013, 132, 493-495.	1.5	12
88	Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNÎ² interact with the endogenous cytokine and activate complement. Clinical Immunology, 2013, 148, 177-185.	1.4	17
89	Challenges and approaches for the development of safer immunomodulatory biologics. Nature Reviews Drug Discovery, 2013, 12, 306-324.	21.5	138
90	T-Cells from HLA-B*57:01+ Human Subjects Are Activated with Abacavir through Two Independent Pathways and Induce Cell Death by Multiple Mechanisms. Chemical Research in Toxicology, 2013, 26, 759-766.	1.7	51

#	Article	IF	Citations
91	Oxidative Bioactivation of Abacavir in Subcellular Fractions of Human Antigen Presenting Cells. Chemical Research in Toxicology, 2013, 26, 1064-1072.	1.7	12
92	Î²-Lactam Antibiotics Form Distinct Haptenic Structures on Albumin and Activate Drug-Specific T-Lymphocyte Responses in Multiallergic Patients with Cystic Fibrosis. Chemical Research in Toxicology, 2013, 26, 963-975.	1.7	50
93	The Generation, Detection, and Effects of Reactive Drug Metabolites. Medicinal Research Reviews, 2013, 33, 985-1080.	5.0	73
94	Detection of Drug Bioactivation in Vivo: Mechanism of Nevirapineâ€"Albumin Conjugate Formation in Patients. Chemical Research in Toxicology, 2013, 26, 575-583.	1.7	39
95	Idiosyncratic Adverse Drug Reactions: Current Concepts. Pharmacological Reviews, 2013, 65, 779-808.	7.1	253
96	Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology, 2013, 57, 727-739.	3.6	212
97	Drug hypersensitivity. , 2012, , 321-330.		6
98	The Development of In Vitro Culture Methods to Characterize Primary T-Cell Responses to Drugs. Toxicological Sciences, 2012, 127, 150-158.	1.4	60
99	Nonimmediate Î²-lactam reactions in patients with cystic fibrosis. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 369-375.	1.1	33
100	Characterization of the Antigen Specificity of T-Cell Clones from Piperacillin-Hypersensitive Patients with Cystic Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 597-610.	1.3	72
101	Research Highlights: Explanation for HLA-B*57:01-linked immune-mediated abacavir-induced hypersensitivity. Pharmacogenomics, 2012, 13, 1567-1569.	0.6	9
102	IL-8 Release from Human Neutrophils Cultured with Pro-Haptenic Chemical Sensitizers. Chemical Research in Toxicology, 2012, 25, 2054-2056.	1.7	5
103	In silico analysis of HLA associations with drug-induced liver injury: use of a HLA-genotyped DNA archive from healthy volunteers. Genome Medicine, 2012, 4, 51.	3.6	58
104	Multiple drug hypersensitivity: normal Treg cell function but enhanced in vivo activation of drugâ€specific T cells. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 58-66.	2.7	47
105	Trimethoprim Stimulates T-Cells through Metabolism-Dependent and -Independent Pathways. Chemical Research in Toxicology, 2011, 24, 791-793.	1.7	4
106	Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis. Journal of Allergy and Clinical Immunology, 2011, 127, 1543-1551.e3.	1.5	43
107	Characterization of drug-specific lymphocyte responses in a patient with drug-induced liver injury. Journal of Allergy and Clinical Immunology, 2011, 128, 680-683.e5.	1.5	12
108	Managing the challenge of chemically reactive metabolites in drug development. Nature Reviews Drug Discovery, 2011, 10, 292-306.	21.5	382

#	Article	IF	Citations
109	Drug bioactivation and protein adduct formation in the pathogenesis of drug-induced toxicity. Chemico-Biological Interactions, 2011, 192, 30-36.	1.7	82
110	Mass Spectrometric Characterization of Circulating and Functional Antigens Derived from Piperacillin in Patients with Cystic Fibrosis. Journal of Immunology, 2011, 187, 200-211.	0.4	101
111	Direct Evidence for the Formation of Diastereoisomeric Benzylpenicilloyl Haptens from Benzylpenicillin and Benzylpenicillenic Acid in Patients. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 841-849.	1.3	78
112	T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assays. Cellular and Molecular Life Sciences, 2010, 67, 4171-4184.	2.4	131
113	Measurement of CD4+ and CD8+ T-Lymphocyte Cytokine Secretion and Gene Expression Changes in p-Phenylenediamine Allergic Patients and Tolerant Individuals. Journal of Investigative Dermatology, 2010, 130, 161-174.	0.3	35
114	Characterization of p-Phenylenediamineâ€"Albumin Binding Sites and T-Cell Responses to Hapten-Modified Protein. Journal of Investigative Dermatology, 2010, 130, 732-742.	0.3	62
115	Drug Antigenicity, Immunogenicity, and Costimulatory Signaling: Evidence for Formation of a Functional Antigen through Immune Cell Metabolism. Journal of Immunology, 2010, 185, 6448-6460.	0.4	53
116	Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Review of Vaccines, 2010, 9, 1007-1016.	2.0	33
117	Stimulation of human T cells with sulfonamides and sulfonamide metabolites. Journal of Allergy and Clinical Immunology, 2010, 125, 411-418.e4.	1.5	109
118	Drug Metabolite-Specific Lymphocyte Responses in Sulfamethoxazole Allergic Patients with Cystic Fibrosis. Chemical Research in Toxicology, 2010, 23, 1009-1011.	1.7	17
119	Metabolic and Chemical Origins of Cross-Reactive Immunological Reactions to Arylamine Benzenesulfonamides: T-Cell Responses to Hydroxylamine and Nitroso Derivatives. Chemical Research in Toxicology, 2010, 23, 184-192.	1.7	25
120	â€œDangerâ€•Conditions Increase Sulfamethoxazole-Protein Adduct Formation in Human Antigen-Presenting Cells. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 372-381.	1.3	48
121	Role of protein haptenation in triggering maturation events in the dendritic cell surrogate cell line THP-1. Toxicology and Applied Pharmacology, 2009, 238, 120-132.	1.3	39
122	Multiple Adduction Reactions of Nitroso Sulfamethoxazole with Cysteinyl Residues of Peptides and Proteins: Implications for Hapten Formation. Chemical Research in Toxicology, 2009, 22, 937-948.	1.7	77
123	A Mechanistic Investigation into the Irreversible Protein Binding and Antigenicity of p-Phenylenediamine. Chemical Research in Toxicology, 2009, 22, 1172-1180.	1.7	41
124	Investigation of the immunogenicity of p-phenylenediamine and Bandrowski's base in the mouse. Toxicology Letters, 2009, 185, 153-159.	0.4	21
125	Activation of T-Cells from Allergic Patients and Volunteers by p-Phenylenediamine and Bandrowski's Base. Journal of Investigative Dermatology, 2008, 128, 897-905.	0.3	48
126	Nonenzymatic Formation of a Novel Hydroxylated Sulfamethoxazole Derivative in Human Liver Microsomes: Implications for Bioanalysis of Sulfamethoxazole Metabolites. Drug Metabolism and Disposition, 2008, 36, 2424-2428.	1.7	4

#	Article	IF	Citations
127	The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity. Current Opinion in Allergy and Clinical Immunology, 2008, 8, 299-307.	1.1	39
128	Sulfamethoxazole and Its Metabolite Nitroso Sulfamethoxazole Stimulate Dendritic Cell Costimulatory Signaling. Journal of Immunology, 2007, 178, 5533-5542.	0.4	111
129	Drug hypersensitivity reactions in patients with HIV disease. Expert Review of Clinical Immunology, 2007, 3, 395-410.	1.3	5
130	Activation of Human Dendritic Cells by p-Phenylenediamine. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 885-892.	1.3	41
131	Immunological principles of T-cell-mediated adverse drug reactions in skin. Expert Opinion on Drug Safety, 2007, 6, 109-124.	1.0	15
132	Drugs as Haptens, Antigens, and Immunogens. , 2007, , 55-65.		8
133	Investigation of the immunogenicity of diclofenac and diclofenac metabolites. Toxicology Letters, 2007, 168, 45-50.	0.4	49
134	Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. Journal of Allergy and Clinical Immunology, 2007, 119, 973-981.	1.5	104
135	Role of bioactivation in drug-induced hypersensitivity reactions. AAPS Journal, 2006, 8, E55-E64.	2.2	60
136	Activation of T cells by carbamazepine and carbamazepine metabolites. Journal of Allergy and Clinical Immunology, 2006, 118, 233-241.	1.5	121
137	The 2nd International Drug Hypersensitivity Meeting. Expert Opinion on Drug Safety, 2006, 5, 729-734.	1.0	2
138	Drug-Specific T Cells in An HIV-Positive Patient with Nevirapine-Induced Hepatitis. Antiviral Therapy, 2006, 11, 393-395.	0.6	12
139	Exposure of mice to the nitroso metabolite of sulfamethoxazole stimulates interleukin 5 production by CD4 T-cells. Toxicology, 2005, 206, 221-231.	2.0	15
140	Carbamazepine-induced acute liver failure as part of the DRESS syndrome. International Journal of Clinical Practice, 2005, 59, 988-991.	0.8	45
141	Investigation of toxic metabolites during drug development. Toxicology and Applied Pharmacology, 2005, 207, 425-434.	1.3	94
142	Characterization of the T-Cell Response in a Patient with Phenindione Hypersensitivity. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 1058-1065.	1.3	18
143	Selective Haptenation of Cellular or Extracellular Protein by Chemical Allergens:Â Association with Cytokine Polarization. Chemical Research in Toxicology, 2005, 18, 375-381.	1.7	70
144	Drug presentation to T cells. Journal of Allergy and Clinical Immunology, 2005, 115, 876-877.	1.5	4

#	Article	IF	Citations
145	Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests. Toxicology, 2004, 194, 179-196.	2.0	60
146	A chemically inert drug can stimulate T cells in vitro by their T cell receptor in non-sensitised individuals. Toxicology, 2004, 197, 47-56.	2.0	53
147	Immunopharmacology of hypersensitivity reactions to drugs. Current Allergy and Asthma Reports, 2003, 3, 22-29.	2.4	38
148	Characterization of drug-specific T cells in lamotrigine hypersensitivity. Journal of Allergy and Clinical Immunology, 2003, 111, 1393-1403.	1.5	198
149	Hypersensitivity Reactions to Carbamazepine: Characterization of the Specificity, Phenotype, and Cytokine Profile of Drug-Specific T Cell Clones. Molecular Pharmacology, 2003, 63, 732-741.	1.0	211
150	Characterization of Sulfamethoxazole and Sulfamethoxazole Metabolite-Specific T-Cell Responses in Animals and Humans. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 229-237.	1.3	68
151	Mechanisms of drug hypersensitivity in HIV-infected patients: the role of the immune system. Journal of HIV Therapy, 2003, 8, 42-7.	0.6	9
152	Covalent Binding of the Nitroso Metabolite of Sulfamethoxazole Leads to Toxicity and Major Histocompatibility Complex-Restricted Antigen Presentation. Molecular Pharmacology, 2002, 62, 628-637.	1.0	129
153	Cellular and Molecular Pathophysiology of Cutaneous Drug Reactions. American Journal of Clinical Dermatology, 2002, 3, 229-238.	3.3	117
154	The danger hypothesisâ€"potential role in idiosyncratic drug reactions. Toxicology, 2002, 181-182, 55-63.	2.0	133
155	Are Chemically Reactive Metabolites Responsible for Adverse Reactions to Drugs?. Current Drug Metabolism, 2002, 3, 351-366.	0.7	56
156	Toxicophores: groups and metabolic routes associated with increased safety risk. Current Opinion in Drug Discovery & Development, 2002, 5, 104-15.	1.9	14
157	Reactive metabolites and their role in drug reactions. Current Opinion in Allergy and Clinical Immunology, 2001, 1, 317-325.	1.1	44
158	Metabolic activation in drug allergies. Toxicology, 2001, 158, 11-23.	2.0	121
159	Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+ T-cells. British Journal of Pharmacology, 2001, 132, 623-630.	2.7	88
160	Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo. British Journal of Pharmacology, 2001, 133, 295-305.	2.7	115
161	Reactive metabolites and their role in drug reactions. Current Opinion in Allergy and Clinical Immunology, 2001, 1, 317-325.	1.1	23
162	Induction of Metabolism-Dependent and -Independent Neutrophil Apoptosis by Clozapine. Molecular Pharmacology, 2000, 58, 207-216.	1.0	120

#	Article	IF	Citations
163	Recognition of Sulfamethoxazole and Its Reactive Metabolites by Drug-Specific CD4+ T Cells from Allergic Individuals. Journal of Immunology, 2000, 164, 6647-6654.	0.4	206
164	Plasma Cysteine Deficiency and Decreased Reduction of Nitrososulfamethoxazole with HIV Infection. AIDS Research and Human Retroviruses, 2000, 16, 1929-1938.	0.5	62
165	Metabolism of Lamotrigine to a Reactive Arene Oxide Intermediate. Chemical Research in Toxicology, 2000, 13, 1075-1081.	1.7	107
166	Immunological Principles of Adverse Drug Reactions. Drug Safety, 2000, 23, 483-507.	1.4	127
167	Cellular disposition of sulphamethoxazole and its metabolites: implications for hypersensitivity. British Journal of Pharmacology, 1999, 126, 1393-1407.	2.7	126
168	Metabolism-Dependent Neutrophil Cytotoxicity of Amodiaquine: A Comparison with Pyronaridine and Related Antimalarial Drugs. Chemical Research in Toxicology, 1998, 11, 1586-1595.	1.7	79
169	Manipulation of the N-alkyl substituent in amodiaquine to overcome the verapamil-sensitive chloroquine resistance component. Antimicrobial Agents and Chemotherapy, 1996, 40, 2345-2349.	1.4	34
170	Synthesis and reactions of nitroso sulphamethoxazole with biological nucleophiles: Implications for immune mediated toxicity. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 1511-1516.	1.0	67
171	Pathology of T-cell-mediated drug hypersensitivity reactions and impact of tolerance mechanisms on patient susceptibility. Current Opinion in Allergy and Clinical Immunology, 0, Publish Ahead of Print, .	1.1	3